Fetal arrhythmias: Ten years’ experience and review of the literature

Basit Öğe Kaydı
dc.authorscopusid57204731546
dc.authorscopusid55338707700
dc.authorscopusid41461297500
dc.authorscopusid58032191000
dc.authorscopusid36570172600
dc.contributor.authorEkici H.
dc.contributor.authorÖkmen F.
dc.contributor.authorİmamoğlu M.
dc.contributor.authorİmamoğlu A.G.
dc.contributor.authorErgenoğlu A.M.
dc.date.accessioned2023-01-12T20:26:23Z
dc.date.available2023-01-12T20:26:23Z
dc.date.issued2022
dc.departmentN/A/Departmenten_US
dc.description.abstractObjective: Fetal arrhythmias complicate 1-2% of all pregnancies. Ultrasound evaluation and Doppler technology are indispensable in both diagnosis and management. Digoxin, sotalol, flecainide and amiodarone are widely accepted antiarrhythmic agents that are frequently. We reviewed the maternal and fetal outcomes in cases with fetal arrhythmia in a tertiary care center in the last decade. Materials and Methods: Fetal arrhythmias were classified under three main groups: Irregular rhythms, tachyarrhythmia and bradyarrhythmia. Detailed anatomical evaluation and fetal echocardiography were performed in all cases to determine whether a structural cardiac and extracardiac anomaly accompanied fetal arrhythmia and the type of fetal arrhythmia. Digoxin was started primarily as first-line therapy in patients with persistent fetal tachyarrhythmia. In cases, not responding to digoxin, other antiarrhythmic agents (sotalol, flecainide) were combined with treatment without discontinuing digoxin. Results: Fetal arrhythmia was detected in 36 cases during the study period. 50% (n=18/36) of the cases had supraventricular tachycardia, whereas 28% (n=10/36) of them were fetal bradyarrhythmia and 22% (n=8/36) of them were with various irregular rhythms. Transplacental therapy was initiated in 13 patients with persistent supraventricular tachycardia and atrial flutter regardless of the presence of hydrops. The success rate in transplacental therapy was 77% (n=10/13). Conclusion: Successful transplacental therapy was achieved in approximately 80% of cases and delivery could be postponed to advanced gestational weeks, confirming the crucial role of this treatment for the management of tachyarrhythmia. ©Copyright 2022 by Turkish Society of Obstetrics and Gynecology.en_US
dc.identifier.doi10.4274/tjod.galenos.2022.61818
dc.identifier.endpage307en_US
dc.identifier.issn21499330
dc.identifier.issn2149-9330en_US
dc.identifier.issue4en_US
dc.identifier.scopus2-s2.0-85144864897en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage302en_US
dc.identifier.urihttps://doi.org/10.4274/tjod.galenos.2022.61818
dc.identifier.urihttps://hdl.handle.net/11454/79998
dc.identifier.volume19en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherTurkish Society of Obstetrics and Gynecologyen_US
dc.relation.ispartofTurkish Journal of Obstetrics and Gynecologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectFetal arrhythmiaen_US
dc.subjectfetal bradyarrhythmiaen_US
dc.subjectfetal tachyarrhythmiaen_US
dc.subjecthydrops fetalisen_US
dc.subjecttransplacental therapyen_US
dc.titleFetal arrhythmias: Ten years’ experience and review of the literatureen_US
dc.title.alternativeFetal aritmiler: On yıllık deneyim ve literatür taramasıen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu